Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Work
Year: 2019
Type: article
Abstract: Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and... more
Source: New England Journal of Medicine
Institutions Institut Gustave Roussy, Université Paris-Sud, Carolina Urologic Research Center, Tampere University, Tampere University Hospital +9 more
Cites: 30
Cited by: 774
Related to: 10
FWCI: 101.7
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze
Funders Bayer, Orionin Tutkimussäätiö